Biochemical Characterization of CTX-M-15 from Enterobacter cloacae and Designing a Novel Non-β-Lactam-β-Lactamase Inhibitor
Open Access
- 21 February 2013
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (2), e56926
- https://doi.org/10.1371/journal.pone.0056926
Abstract
The worldwide dissemination of CTX-M type β-lactamases is a threat to human health. Previously, we have reported the spread of blaCTX-M-15 gene in different clinical strains of Enterobacteriaceae from the hospital settings of Aligarh in north India. In view of the varying resistance pattern against cephalosporins and other β-lactam antibiotics, we intended to understand the correlation between MICs and catalytic activity of CTX-M-15. In this study, steady-state kinetic parameters and MICs were determined on E. coli DH5α transformed with blaCTX-M-15 gene that was cloned from Enterobacter cloacae (EC-15) strain of clinical background. The effect of conventional β-lactamase inhibitors (clavulanic acid, sulbactam and tazobactam) on CTX-M-15 was also studied. We have found that tazobactam is the best among these inhibitors against CTX-M-15. The inhibition characteristic of tazobactam is defined by its very low IC50 value (6 nM), high affinity (Ki = 0.017 µM) and better acylation efficiency (k+2/K′ = 0.44 µM−1s−1). It forms an acyl-enzyme covalent complex, which is quite stable (k+3 = 0.0057 s−1). Since increasing resistance has been reported against conventional β-lactam antibiotic-inhibitor combinations, we aspire to design a non-β-lactam core containing β-lactamase inhibitor. For this, we screened ZINC database and performed molecular docking to identify a potential non-β-lactam based inhibitor (ZINC03787097). The MICs of cephalosporin antibiotics in combination with this inhibitor gave promising results. Steady-state kinetics and molecular docking studies showed that ZINC03787097 is a reversible inhibitor which binds non-covalently to the active site of the enzyme through hydrogen bonds and hydrophobic interactions. Though, it’s IC50 (180 nM) is much higher than tazobactam, it has good affinity for CTX-M-15 (Ki = 0.388 µM). This study concludes that ZINC03787097 compound can be used as seed molecule to design more efficient non-β-lactam containing β-lactamase inhibitor that could evade pre-existing bacterial resistance mechanisms.This publication has 55 references indexed in Scilit:
- Distant and New Mutations in CTX-M-1 β-Lactamase Affect Cefotaxime HydrolysisAntimicrobial Agents and Chemotherapy, 2011
- Exploring the Inhibition of CTX-M-9 by β-Lactamase Inhibitors and CarbapenemsAntimicrobial Agents and Chemotherapy, 2011
- CTX-M-93, a CTX-M Variant Lacking Penicillin Hydrolytic ActivityAntimicrobial Agents and Chemotherapy, 2011
- Functional Role of Glutamine 28 and Arginine 39 in Double Stranded RNA Cleavage by Human Pancreatic RibonucleasePLOS ONE, 2011
- Mechanistic Studies of the Inactivation of TEM-1 and P99 by NXL104, a Novel Non-β-Lactam β-Lactamase InhibitorAntimicrobial Agents and Chemotherapy, 2010
- Bench-to-bedside review: The role of β-lactamases in antibiotic-resistant Gram-negative infectionsCritical Care, 2010
- Infected foot ulcers in male and female diabetic patients: a clinico-bioinformative studyAnnals of Clinical Microbiology and Antimicrobials, 2010
- Three Decades of β-Lactamase InhibitorsClinical Microbiology Reviews, 2010
- Identification of CTX-M-Type Extended-Spectrum-β-Lactamase Genes Using Real-Time PCR and PyrosequencingAntimicrobial Agents and Chemotherapy, 2007
- Extended-Spectrum β-Lactamases: a Clinical UpdateClinical Microbiology Reviews, 2005